• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human B-cell CLL/lymphoma 9-like protein (BCL9L), Truncated

ACP15636

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP15636 Target NameBCL9L
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Protein LengthPartialPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ86UU0
Background Information
  • Uniprot Id

    Q86UU0

  • Target Species

    Human

  • Target Name

    BCL9L

  • Target Full Name

    B-cell CLL/lymphoma 9-like protein

  • Target Function

    Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1.

  • Target Subcellular Location

    Nucleus.

  • Target Protein Families

    BCL9 family

  • Target Tissue Specificity

    Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck

  • Target Synonyms

    B-cell CLL; B-cell CLL/lymphoma 9-like protein; B-cell lymphoma 9-like protein; B9L; BCL9-2; BCL9-like protein; BCL9-related beta-catenin-binding protein; Bcl9l; BCL9L_HUMAN; DLNB11; Nuclear co factor of beta catenin signalling; Protein BCL9-2

Inquire Recombinant Human B-cell CLL/lymphoma 9-like protein (BCL9L), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification